Asset Details
Do you wish to reserve the book?
Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs
Do you wish to request the book?
Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs
2005
Overview
OBJECTIVE:--Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS--This 28-week parallel-group study randomized 233 insulin-naive patients with HbA[subscript 1c] values [>/=]8.0% on >1,000 mg/day metformin alone or in combination with other OADs. Metformin was adjusted up to 2,550 mg/day before insulin therapy was initiated with 5-6 units BIAsp 70/30 twice daily or 10-12 units glargine at bedtime and titrated to target blood glucose (80-110 mg/dl) by algorithm-directed titration. RESULTS:--A total of 209 subjects completed the study. At study end, the mean HbA[subscript 1c] value was lower in the BIAsp 70/30 group than in the glargine group (6.91 ± 1.17 vs. 7.41 ± 1.24%, P < 0.01). The HbA[subscript 1c] reduction was greater in the BIAsp 70/30 group than in the glargine group (-2.79 ± 0.11 vs. -2.36 ± 0.11%, respectively; P < 0.01), especially for subjects with baseline HbA[subscript 1c] >8.5% (-3.13 ± 1.63 vs. -2.60 ± 1.50%, respectively; P < 0.05). More BIAsp 70/30-treated subjects reached target HbA[subscript 1c] values than glargine-treated subjects (HbA[subscript 1c] 8.5%.
Publisher
American Diabetes Association
Subject
/ Adult
/ Biological and medical sciences
/ Blood Glucose - drug effects
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes. Impaired glucose tolerance
/ Endocrine pancreas. Apud cells (diseases)
/ Female
/ Glycated Hemoglobin A - metabolism
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Insulin
/ Insulin - administration & dosage
/ Insulin - analogs & derivatives
/ Male
/ Metformin - administration & dosage
/ noninsulin-dependent diabetes mellitus
/ patients
